Sanofi (China) Investment Co., Ltd., Lactacyd, originated in France, is the world's leading brand of women's daily care lotion, and a diversified pharmaceutical and health enterprise integrating research and development of vaccines, prescription drugs, health pharmaceutical products and animal health products
In the 19th century, the European gynecologist Doderlin discovered that there are naturally beneficial bacteria (lactic acid bacteria) in women's private parts to resist harmful bacteria and protect the health of private parts;
In 1957, the French company Sanofi Aventis joined hands with European gynecology experts to create the first bottle of "Lingteshi" and successfully launched it, and the professional era of women's care began.
In the 80s, "Lingte" came to Asia, and then spread to Hong Kong, Singapore and Southeast Asian countries.
In 2009, it became the world's leading selling women's daily care lotion, and tens of millions of women around the world use Lingteshi every day;
In 2011, it landed in China for the first time and joined hands with the Chinese Medical Doctor Association to care for Chinese women's health.
Sanofi Group is a leading global diversified pharmaceutical and health company, focusing on the needs of patients and spreading health. Sanofi's businesses cover vaccines, prescription drugs, health pharmaceutical products and animal health products, with more than 100,000 employees in more than 100 countries.
Sanofi Pasteur, the Group's vaccine division, is the world's largest manufacturer of human vaccines, with an annual production capacity of 1 billion doses of vaccines, which can prevent 20 diseases and protect more than 500 million people worldwide.
The Group's six core growth platforms for sustainable development are emerging markets, vaccines, health pharmaceuticals, diabetes treatments and innovative products. In 2010, the Group's net sales amounted to 30.4 billion euros, of which emerging markets accounted for 30 percent of the Group's sales, leading the world's emerging markets.
As a sustainable growth platform, the Group's R&D department is committed to providing treatment options for patients, and currently has 55 new compounds and vaccine products in the R&D stage, of which 13 compounds and vaccines have entered the Phase III and registration stage.
Corporate Social Responsibility (CSR) is at the core of Sanofi's business, and the Group's achievements in fulfilling CSR have received the attention of many institutions (rating agencies, NGOs, research institutes, universities, etc.). In 2010, Sanofi was once again ranked among the world's most authoritative CSR indices.
Sanofi has always been committed to China. In 1982, Sanofi opened an office in China, and now has more than 6,000 employees in China, making it one of the fastest-growing pharmaceutical and health companies in China. Sanofi is headquartered in Shanghai and has 11 regional offices in Beijing, Tianjin, Shenyang, Jinan, Shanghai, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou and Urumqi.
